07:38 AM EDT, 06/25/2025 (MT Newswires) -- Amicus Therapeutics ( FOLD ) said Wednesday it has received the approval of Japan's Ministry of Health, Labour and Welfare for the combination of Pombiliti and Opfolda to treat adult patients with late-onset Pompe disease.

The approval was based on clinical data from a phase 3 trial, the company said, adding that the combination therapy now has approval in the US, EU, UK, Australia, Canada, Japan and Switzerland.